作者
Antonino Tuttolomondo, Anna Cirrincione, Alessandra Casuccio, Alessandro Del Cuore, Mario Daidone, Tiziana Di Chiara, Domenico Di Raimondo, Vittoriano Della Corte, Carlo Maida, Irene Simonetta, Stefania Scaglione, Antonio Pinto
发表日期
2021/12
期刊
Cardiovascular diabetology
卷号
20
页码范围
1-14
出版商
BioMed Central
简介
Background
Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage.
Aims
We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
Methods
Men and women (aged ≥ 50 years …
学术搜索中的文章
A Tuttolomondo, A Cirrincione, A Casuccio… - Cardiovascular diabetology, 2021